Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx (NASDAQ: RARE) granted 65,886 restricted stock units (RSUs) of its common stock to 39 newly hired non-executive officers under the Ultragenyx Employment Inducement Plan.

Rhea-AI Summary

Ultragenyx (NASDAQ: RARE) granted 65,886 restricted stock units (RSUs) of its common stock to 39 newly hired non-executive officers under the Ultragenyx Employment Inducement Plan. The RSUs, granted on July 16, 2026, vest over four years at 25% per year, subject to continued employment.

Argus Jul 27 session 1 alert

-0.04% close to close 0.5x rel. volume Open Argus

Details

News Market Reaction – RARE

$2.65B Market Cap

On Jul 27, the first trading day after this news, RARE closed 0.04% below the previous close.

Data tracked by StockTitan Argus for the Jul 27 session.

Key Figures

Restricted Stock Units: 65,886 RSUs Recipients: 39 officers Grant Date: July 16, 2026 +2 more

Restricted Stock Units

65,886 RSUs

Granted to newly hired employees

Recipients

39 officers

Newly hired non-executive officers

Grant Date

July 16, 2026

Inducement award grant date

Vesting Period

4 years

RSU vesting schedule

Annual Vesting

25%

Underlying shares vest on each anniversary

Historical Context

5 past events · Latest: Jul 08

5 events

1. Jul 08

   Impact report

   24h Move

   -3.4%

   Released 2025 impact report covering rare-disease patients, innovation, access, and governance

2. Jun 19

   Inducement grant

   24h Move

   +5.8%

   Inducement equity grant to 15 newly hired non-executive officers under Nasdaq rule

3. Jun 03

   Conference participation

   24h Move

   +4.0%

   Planned CEO participation in Goldman Sachs healthcare conference fireside chat

4. May 22

   Inducement grant

   24h Move

   -1.1%

   Granted 17,567 restricted stock units to 11 newly hired non-executive officers

5. May 06

   Conference participation

   24h Move

   +0.8%

   Scheduled executive fireside appearance at Bank of America's healthcare conference

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), inducement grant

3 terms

restricted stock units financial

"reported the grant of 65,886 restricted stock units of the company’s common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement grant financial

"Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"

An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NOVATO, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 65,886 restricted stock units of the company’s common stock to 39 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of July 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement equity grant did Ultragenyx (RARE) announce on July 24, 2026?

Ultragenyx announced an equity inducement grant of 65,886 restricted stock units (RSUs) to 39 newly hired non-executive officers. According to Ultragenyx, the RSUs were granted under its Employment Inducement Plan with a grant date of July 16, 2026, as a material employment inducement.

How many employees are included in the July 2026 Ultragenyx (RARE) inducement RSU grant?

Ultragenyx granted inducement RSUs to 39 newly hired non-executive officers. According to Ultragenyx, these awards were approved by the board’s compensation committee and are intended as a material inducement for the new employees to enter into employment with the company under Nasdaq Listing Rule 5635(c)(4).

What is the vesting schedule for the 65,886 Ultragenyx (RARE) inducement RSUs granted in July 2026?

The 65,886 inducement RSUs vest over four years at 25% per year. According to Ultragenyx, 25% of the underlying shares vest on each anniversary of the July 16, 2026 grant date, contingent on the employee’s continuous employment on each vesting date.

Under which plan were the July 16, 2026 Ultragenyx (RARE) inducement RSUs granted?

The July 16, 2026 inducement RSUs were granted under the Ultragenyx Employment Inducement Plan. According to Ultragenyx, these awards were approved by the compensation committee and structured to comply with Nasdaq Listing Rule 5635(c)(4) as a material inducement to new employees entering employment.

How does Nasdaq Listing Rule 5635(c)(4) relate to Ultragenyx’s July 2026 RSU grant (RARE)?

The July 2026 RSU grant was made in reliance on Nasdaq Listing Rule 5635(c)(4), which permits inducement equity awards. According to Ultragenyx, the RSUs were granted as a material inducement for 39 newly hired non-executive officers to enter into employment with the company.